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RESUMO 
Os astrócitos são células altamente dinâmicas que mantêm a homeostase do sistema nervoso 
central, bem como, regulam sistemas de neurotransmissores e atuam no processamento das in-
formações sinápticas, do metabolismo energético, das defesas antioxidantes e da resposta infla-
matória. Baseado nisso, o cultivo dessas células vêm sendo amplamente utilizadas para estudos 
metabólicos referentes à resposta inflamatória, ao estresse oxidativo, ao sistema glutamatérgico 
e à senescência. Manter o microambiente celular asséptico é fundamental para que possamos 
entender a funcionalidade astrocitária in vitro sem inferência de microrganismos, para isso co-
mumente é realizada a adição de antimicrobianos aos meios de cultivos. A partir disso, perce-
bemos que existe uma carência de protocolos padronizados na literatura acerca das classes e 
concentrações desses fármacos. Portanto, neste trabalho avaliamos alterações em parâmetros 
glutamatérgicos, oxidativos e inflamatórios em culturas de astrócitos frente aos antimicrobianos 
gentamicina e penicilina/estreptomicina adicionados ao meio de cultivo em diferentes concen-
trações. Nas células cultivadas com gentamicina foram observadas algumas alterações no me-
tabolismo energético, como o aumento da captação de glutamato dose-dependente e a diminui-
ção da captação de glicose e do transportador de glicose tipo 1 (GLUT1). Também foi obser-
vado aumento nos níveis de glutationa (GSH), porém nenhuma alteração na atividade da enzima 
superóxido dismutase foi encontrada. Ainda, observamos uma elevação nos níveis de interleu-
cina (IL)-1β e uma redução nos níveis de IL-10.  Já as células cultivadas com penicilina/estrep-
tomicina também apresentaram variações no metabolismo energético como: aumento da capta-
ção de glutamato dose-dependente e aumento da captação de glicose. Além disso, foram nota-
das alterações no citoesqueleto de actina e elevação nos níveis de IL-6. Tais achados sugerem, 
portanto, que a adição desses fármacos ao meio de cultivo interfere nas funções metabólicas 
astrocitárias. Logo, o uso não padronizado desses antimicrobianos pode explicar as discrepân-
cias entre experimentos realizados por diferentes grupos de pesquisas. 
Palavras-chave: astrócitos, antimicrobianos, gentamicina, penicilina, estreptomicina.  
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ABSTRACT 
Astrocytes are dynamic glial cells that maintain central nervous system homeostasis, regulating 
neurotransmitter systems, and process synaptic information, energy metabolism, antioxidant 
defenses, and inflammatory response. In the sense, astrocyte cultures have been widely used as 
tool for metabolic studies concerning the inflammatory response, oxidative stress, glutama-
tergic system and senescence. In order to obtain reliable results, these cultures need to be aseptic 
and it is commonly obtained through the addition of antimicrobials to the culture medium. In 
line with this, we noticed that there is a lack of protocols in the literature about the class and 
concentration of these drugs added to the culture medium. Therefore, in this work, we evaluated 
changes in glutamatergic, oxidative and inflammatory parameters in primary astrocytes cul-
tured with the antimicrobials gentamicin and penicillin/streptomycin in different doses. Cells 
cultivated with gentamicin presented changes in energy metabolism, such as a dose-dependent 
increase in glutamate uptake and a decrease in glucose uptake and in the expression of glucose 
transporters type 1 (GLUT1). We also observed an increase in glutathione (GSH) levels, but no 
change in superoxide dismutase activity. Additionally, an increase in interleukin (IL)-1β levels 
and a reduction in IL-10 levels were observed. Astrocytes cultivated with penicillin/streptomy-
cin also presented variations in energy metabolism: a dose-dependent increase in glutamate 
uptake as well as in glucose uptake. Furthermore, actin cytoskeleton and IL-6 levels were also 
changed. Such findings suggest that the addition of antimicrobials to the culture medium alters 
the astrocyte metabolism. Therefore, the non-standard use of these drugs might explain changes 
between experiments performed by different research groups. 
 
Keywords: astrocytes, antimicrobials, gentamicin, penicillin, streptomycin. 
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1. INTRODUÇÃO 
1.1 SISTEMA NERVOSO CENTRAL  
O  parênquima do sistema nervoso central (SNC) é constituído por dois grandes tipos 
celulares: os neurônios, responsáveis pela transmissão e processamento de informações, e as 
células gliais, que possuem diversos papéis que garantem o adequado funcionamento cerebral 
(Brady et al., 2012). As células gliais são divididas em oligodendrócitos, microglia e astrócitos. 
Os oligodendrócitos são responsáveis principalmente pela síntese de mielina, as células micro-
gliais são as células fagocíticas envolvidas principalmente na resposta inflamatória e as células 
astrocitárias desempenham uma série de funções essenciais para a homeostase do SNC (Gomes 
et al., 2013), destacam-se, estas, como componentes majoritários (Raine et al., 2006; 
Kettenmann et al., 2008).  
1.2 ASTRÓCITOS  
 Em 1846, o patologista Rudolf Virchow descreveu pela primeira vez a neuroglia e a 
caracterizou como sendo células pequenas e de forma arredondada, que preenchiam o espaço 
extracelular e faziam parte do tecido conectivo (Somjen et al., 1988). Os astrócitos constituem 
aproximadamente 50% do número total de células do SNC. Possuindo, ainda, a maior diversi-
dade funcional do cérebro com uma capacidade dinâmica de modificar seu fenótipo no decorrer 
da vida (Shao et al., 1994).  Com o avanço das técnicas o estudo das propriedades do SNC, a 
compreensão sobre a funcionalidade das células astrocitárias apresenta-se muito mais complexa 
e importante do que se imaginava anteriormente. 
Os astrócitos são células altamente variáveis em sua morfologia e função, sendo cruciais 
para a manutenção da homeostase do SNC. Estas células são responsáveis por captar glutamato 
– o principal neurotransmissor excitatório do SNC – através da atividade dos transportadores 
de glutamato-1 (GLT-1) e transportador glutamato-aspartato (GLAST) (Anderson et al., 2000; 
Danbolt et al., 2001). Os astrócitos também são essenciais na conversão de glutamato em glu-
tamina através da enzima glutamina sintetase (GS), sendo a glutamina  gerada  nos astrócitos  
por  essa  enzima e lançada  de  volta  para  os terminais pré-sinápticos para ser utilizada na 
síntese de novo do neurotransmissor glutamato nos neurônios (Schousboe et al., 2013). Após 
essa conversão, o glutamato pode ser utilizado como uma importante fonte energética neuronal 
(Bak et al. 2006).  
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Entretanto, o substrato mais utilizado nas demandas energéticas cerebrais é a glicose e 
os astrócitos também expressam transportadores de glicose do tipo 1 (GLUT1) na membrana 
dos seus processos celulares adjacentes aos capilares sanguíneos (Mergenthaler et al., 2013; 
Benarroch et al., 2014). Desta maneira, eles captam glicose do sangue e a utilizam, em parte 
oxidativamente, para gerar ATP e suprir a energia necessária para suas rotas metabólicas, e em 
parte anaerobicamente, levando a um aumento do lactato intracelular (Pellerin et al., 2002).         
Além disso, os astrócitos são essenciais para a manutenção das defesas antioxidantes no 
SNC. Esse sistema de defesa antioxidante pode ser dividido em não enzimático e enzimático. 
Em relação à defesa antioxidante não enzimática, os astrócitos são responsáveis pela síntese de 
glutationa (GSH), um tripeptídeo formado pelos aminoácidos glutamato, cisteína e glicina, que 
exerce seu efeito antioxidante reagindo diretamente com as espécies reativas de oxigênio 
(EROs) (Pope et al., 2008). Paralelamente, no que se refere à defesa antioxidante enzimática, 
devem ser destacadas as três principais enzimas antioxidantes: (1) superóxido dismutase 
(SOD), capaz de dismutar o radical superóxido a peróxido de hidrogênio; (2) catalase (CAT), 
responsável por detoxificar o peróxido de hidrogênio a oxigênio e água; e (3) glutationa pero-
xidase (GPx) agente inativador de peróxidos orgânicos e que possui importância vital na redu-
ção dos níveis de GSH (Bélanger et al., 2009; Kimelberg el al., 2010). 
Ainda na abrangência de suas funções, essas células também são capazes de reconhecer 
os eventos iniciais do processo inflamatório, bem como responder e amplificar a sinalização 
microglial (Wang et al., 2008). Durante o processo inflamatório os astrócitos liberam uma gama 
de citocinas anti e pró-inflamatórias com intuito de atrair leucócitos e aumentar sua proliferação 
no local da inflamação (Jensen et al., 2013). Em relação às citocinas anti-inflamatórias liberadas 
pelos astrócitos pode ser ressaltada a interleucina - 10 (IL-10), a qual pode manter a homeostase 
imune (Oliveira et al., 2016). Por outro lado, dentre as principais citocinas pró-inflamatórias 
produzidas e secretadas por astrócitos, estão o fator de necrose tumoral α (TNF-α), a interleu-
cina 1β (IL-1β) e a interleucina-6 (IL-6) (Jensen et al., 2013). Estes mediadores inflamatórios 
quando secretadas pelo astrócitos, são responsáveis por induzir o aumento do processo infla-
matório (Oliveira et al., 2016).  
Outro importante papel dos astrócitos é sua capacidade de responder a lesões no SNC, 
sejam elas resultantes de patologias, traumas, insultos químicos ou doenças genéticas, através 
da ativação do processo de astrogliose (ou gliose reativa) (Sofroniew et al., 2009). Os astrócitos 
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possuem uma proteína marcadora de diferenciação celular, a proteína glial fibrilar ácida 
(GFAP), uma proteína que apresenta filamentos intermediários do tipo III e peso molecular 
aparente de 50kDa (Bramanti et al., 2010; Yang et al., 2015). Com o intuito de conter os danos 
causados por diferentes lesões, os astrócitos alteram sua morfologia e se proliferam, tornando-
se reativos (processo caracterizado por rápida síntese de filamentos intermediários de GFAP) 
formando uma cicatriz glial, que impede a proliferação, principalmente, de mediadores infla-
matórios (Sofroniew et al., 2009). 
1.3 CULTURA DE ASTRÓCITOS CORTICAIS 
 Como os astrócitos são responsáveis por inúmeras e distintas funções relacionadas à 
homeostase do SNC, a cultura dessas células pode ser utilizada para caracterizar propriedades 
bioquímicas, farmacológicas e morfológicas do SNC. Essa metodologia vem sendo ampla-
mente utilizada como modelo para estudos metabólicos relacionados à resposta inflamatória, 
ao estresse oxidativo, ao sistema glutamatérgico e à senescência (Pertusa et al., 2007; Xiang et 
al., 2014; Bakshi et al., 2015; Copetti-Santos et al., 2015). 
Com base nisso, nos últimos anos, nosso grupo - assim como outros - vem buscando 
elucidar o papel dos astrócitos em situações patológicas que acometem o SNC (Bellaver et al., 
2015b, 2016; Caito et al., 2013; Xiang et al., 2014), uma vez que essas células emergem como 
um promissor alvo para moléculas profilático-terapêuticas. A cultura de células consiste em 
processos de isolamento e manutenção da viabilidade e da proliferação celular de um determi-
nado tipo de tecido. Isso ocorre em um sistema in vitro constituído por nutrientes e fatores 
essenciais para sua sobrevivência perante condições específicas de temperatura, pH e osmola-
ridade (Barbosa et al., 2015).  
 Em 1961, Hayflick&Moorhead foram pioneiros no uso de antibióticos para prevenir a 
contaminação bacteriana em cultivos celulares, onde a adição desses fármacos aos meios de 
cultivo permitiu que a técnica fosse continuadamente disseminada e utilizada  arbosa et al., 
2015). Para a manutenção destas culturas, observa-se na literatura a adição não padronizada de 
antimicrobianos de diferentes classes e em diferentes concentrações ao meio de cultivo 
(Meshitsuka et al., 2008; Zhu et al., 2015). Apesar de se acreditar que os antibióticos possam 
influenciar no modo como as culturas celulares respondem aos estímulos a que são expostas, 
ainda não existem estudos robustos relacionados a tal tema. 
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1.4 ANTIMICROBIANOS 
Antimicrobianos são compostos naturais, sintéticos ou semi-sintéticos, que são capazes 
de inibir o crescimento ou causar a morte de fungos ou bactérias; sendo eles classificados como 
bacteriostáticos ou bactericidas, respectivamente (Walsh et  al., 2003). Após a descoberta da 
penicilina por Alexander Fleming, em 1928, vários outros antimicrobianos foram descobertos 
e aprimorados, como a estreptomicina e a gentamicina, ambos da classe dos aminoglicosídeos 
(Guimarães et al., 2010).  
A penicilina é classicamente obtida a partir de um extrato de cultura fluida do fungo 
Penicillium notatum e pertence ao grupo dos betalactâmicos – antibióticos que possuem o anel 
azetidinona de quatro membros (ou anel betalactâmico). Seu núcleo fundamental – ácido 6-
aminopenicilênico – é o requisito estrutural para sua atividade biológica, que faz com que este 
antimicrobiano aja de modo eficaz contra bactérias gram-positivas e apresente baixa toxicidade 
(Guimarães et al. 2010). Esse fármaco tem como alvo a enzima transpeptidase e atua inibindo 
a formação de ligação cruzada entre cadeias de peptideoglicano, impedindo a formação correta 
da parede celular bacteriana (Suárez et al., 2009; Guimarães et al., 2010). 
A estreptomicina, por sua vez, é isolada a partir de um microrganismo do solo, o Strep-
tomyces griseus, e é efetiva contra bactérias gram-negativas. Esse fármaco pertence ao grupo 
dos aminoglicosídios e apresenta efeito bactericida por ligar-se especificamente à subunidade 
30S dos ribossomos bacterianos. Isso impede o movimento do ribossomo ao longo do RNAm 
e, consequentemente, interrompe a síntese proteica (Doi et al., 2016; Guimarães et al., 2010). 
A estreptomicina pode ser administrada pelas vias intramuscular profunda e intravenosa e, por 
possuir elevada toxicidade (Brunton et al., 2012), geralmente é administrada em associação a 
outros fármacos, como ocorre com sua combinação à penicilina, a qual promove um efeito 
bactericida sinérgico (Guimarães et al., 2010; Wargo et al., 2014). Paralelamente, devido a sua 
alta toxicidade e ao fato de ser menos ativa do que outros membros de sua classe contra basto-
netes gram-negativos aeróbicos (Brunton et al., 2012), esse antibiótico não é mais utilizado em 
monoterapias, o que faz com que seja substituído por outros fármacos. 
Para substituições monoterápicas, o antibiótico substituto costuma ser a gentamicina, a 
qual é utilizada no tratamento de infecções graves causadas por bactérias gram-negativas resis-
tentes a outros fármacos, embora ela também apresente um certo grau de toxicidade (Brunton 
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et al., 2012; Destache et al., 2014). A gentamicina, que também faz parte da classe dos amino-
glicosídeos, é produzida por um actinomiceto – Micromonospora purpúrea (Ghaffar et al., 
2015). Seu mecanismo de ação, semelhante ao citado para a estreptomicina, consiste na inter-
rupção da síntese proteica (Guimarães et al., 2010). Muitos tipos diferentes de infecções podem 
ser tratadas com esse antibiótico; todavia, devido a sua moderada toxicidade, o uso prolongado 
deve ser restrito ao combate às infecções potencialmente fatais e àquelas em que um agente 
menos tóxico é contraindicado ou é menos efetivo (Brunton et al., 2012). 
Por fim, todos os antibióticos citados anteriormente são utilizados tanto no tratamento 
de patologias in vivo quanto em técnicas laboratoriais in vitro. Diferentes concentrações destes 
antimicrobianos são extensivamente utilizadas em meios de cultivo celular, sendo a utilização 
deles considerada apenas como uma medida adicional de segurança, não como um método de 
esterilização dos meios de cultura. Além disso, estes antimicrobianos são utilizados, na maioria 
dos casos, apenas como viabilizadores do cultivo celular, não devendo influenciar nas funções 
celulares propriamente ditas. Considerando isso, na escolha do antibiótico, deve-se principal-
mente levar em conta dois fatores: o grau de citotoxicidade do antibiótico e a resposta celular 
do mesmo, uma vez que a interação entre ambos é muito variada (Freshney et al., 2006; Belenky 
et al., 2015). 
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2. JUSTIFICATIVA 
 Considerando: i) a ampla utilização da cultura de astrócitos como ferramenta de estudos 
para elucidar o papel destas células em modelos experimentais, ii) a utilização não padronizada 
de antibióticos por diferentes grupos de pesquisa no preparo da cultura astrocitária, e iii) a pos-
sibilidade da obtenção de resultados não fidedignos devido ao uso variável destes antimicrobi-
anos, torna-se relevante elucidar o efeito de diferentes classes/concentrações de antimicrobia-
nos em culturas de astrócitos. Portanto, esse trabalho de conclusão de curso contribui para elu-
cidar a influência que os antimicrobianos podem exercer sobre a funcionalidade astrocitária 
basal e ainda ajuda a esclarecer divergências observadas em estudos com culturas de astrócitos 
realizadas por diferentes grupos de pesquisa. 
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3. OBJETIVO GERAL 
 Avaliar alterações em parâmetros glutamatérgicos, oxidativos e inflamatórios relacio-
nadas à utilização de diferentes classes e concentrações de antimicrobianos em culturas primá-
rias de astrócitos corticais. 
3.1 OBJETIVO ESPECÍFICO 1 
 Verificar alterações em proteínas gliais e em parâmetros glutamatérgicos a partir da cul-
tura de astrócitos em um meio de cultivo contendo penicilina/estreptomicina ou gentamicina, 
ambos em diferentes concentrações. Para este fim, os seguintes parâmetros foram avaliados: (a) 
imunoconteúdo de GFAP, (b) captação de glutamato, (c) imunoconteúdo dos transportadores 
GLT-1 e GLAST e (d) atividade e imunoconteúdo da enzima GS. 
3.2 OBJETIVO ESPECÍFICO 2 
 Avaliar se diferentes classes e concentrações de antimicrobianos promovem alterações 
na captação de glicose astrocitária. Para isso, após as culturas terem sido mantidas em meio 
contendo penicilina/estreptomicina ou gentamicina, os seguintes parâmetros foram avaliados: 
(a) captação de glicose e (b) imunoconteúdo de GLUT1. 
3.3 OBJETIVO ESPECÍFICO 3 
 Verificar se alterações em classes e concentrações de antimicrobianos promovem alte-
rações em parâmetros oxidativos. Visando alcançar isso, após as culturas terem sido mantidas 
em meio contendo penicilina/estreptomicina ou gentamicina, os seguintes parâmetros foram 
avaliados: (a) níveis de GSH e (b) atividade da enzima antioxidante SOD. 
3.4 OBJETIVO ESPECÍFICO 4 
 Determinar alterações inflamatórias em culturas primárias de astrócitos corticais expos-
tos a diferentes classes e concentrações de antimicrobianos. Para essa determinação, os seguin-
tes parâmetros foram avaliados: (a) TNF-α, IL-1β, IL-6 e IL-10. 
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ABSTRACT 
Astrocytes are dynamic glial cells that maintain central nervous system homeostasis, 
processing synaptic information and regulating neurotransmitter systems, energy metabolism, 
antioxidant defenses, and inflammatory response. In this sense, astrocyte cultures have been 
widely used as tool for studies concerning glial functionality. In order to obtain reliable results, 
these cultures need to be aseptic and it is commonly obtained through the addition of antimi-
crobials to the culture medium. In line with this, we noticed that there is a lack of protocols in 
literature about the class and concentration of these drugs added to the culture medium. Hence, 
in this work we evaluated the changes in glutamatergic, oxidative and inflammatory parameters 
of astrocytes primary cultured with the antimicrobials gentamicin and penicillin/streptomycin 
at different doses. Cells were cultivated with gentamicin presented changes in energy metabo-
lism, such as a dose-dependent increase in glutamate uptake and a decrease in glucose uptake 
as well as in the expression of glucose transporters type 1 (GLUT1). We also observed an in-
crease in glutathione (GSH) levels, as well as levels of interleukin (IL)-1β and a reduction of 
IL-10. Astrocytes cultivated with penicillin/streptomycin also presented variations in energy 
metabolism: a dose-dependent increase in glutamate uptake and glucose uptake. In addition, 
actin cytoskeleton and IL-6 levels were also changed. Such findings suggest that the addition 
of antimicrobials to the culture medium alters the astrocyte metabolism. Therefore, the non-
standard use of these drugs might explain between experiments performed by different research 
groups. 
 
Keywords: astrocytes, cultures, antimicrobials, gentamicin, penicillin, streptomycin 
 
 
 
 
 
 
18 
 
  
 
1. INTRODUCTION 
Astrocytes are important cells in the central nervous system (CNS), they are involved 
in the maintenance of the extracellular environment and in the stabilization of cell-cell commu-
nications under physiological and pathological conditions [1–5]. These cells participate in a 
diverse CNS functions, including regulation of neurotransmitter systems, ionic homeostasis, 
metabolic support, energy metabolism, synaptic information processing (as part of the tripartite 
synapse), plasticity and neuronal excitability, antioxidant defenses, the maintenance of the 
blood-brain barrier, and inflammatory response [1–3, 6–10]. These cells release anti- and pro-
inflammatory cytokines in regenerative or protective processes such as interleukin (IL)-10, IL-
1β, IL-6, and tumor necrosis factor α (TNF- α), respectively [11]. Astrocytes also have a char-
acteristic marking of cell differentiation, a glial fibrillary acidic protein (GFAP), an intermedi-
ate type III filament that can be altered when the CNS suffers injury [12, 13]. 
Astrocytes are also crucial cells in glutamatergic transmission homeostasis performing 
glutamate uptake through high-affinity glutamate transporters: glutamate transporter-1 (GLT-
1) and glutamate aspartate transporter (GLAST) [14–17]. This glutamate might be used as a 
substrate for oxidation in the tricarboxylic acid cycle, synthesize the tripeptide glutathione 
(GSH) – the major brain antioxidant – or glutamine through the enzyme glutamine synthetase 
(GS) [18–21]. Moreover, astrocyte cells take up glucose through type 1 glucose transporters 
(GLUT1) [1, 22, 23]. 
Cultured astrocytes have been extensively used to characterize the biochemical, phar-
macological and morphological properties of the CNS. Based on that, several studies sought to 
elucidate the role of astrocytes in physiological and pathological conditions [24–27], since these 
cells emerge as a promising target for prophylactic therapeutic molecules. Cell cultures consist 
in the isolation and maintenance of a certain type of tissueto maintain viability and cell prolif-
eration. This occurs in an in vitro system a favorable environment for cell survival [28]. 
In order to maintain the cellular environment without contamination, different protocols 
added antimicrobial agents to the culture medium. Generally, they are added non-standardized 
in relation to both classes and concentrations [29–31]. These drugs must have not influence in 
the cellular responses, although there are few studies elucidating the impact of antimicrobial 
drugs in astrocyte functionality. The most common antimicrobials added to the culture medium 
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are gentamicin (aminoglycosides), penicillin (beta lactam) and streptomycin (aminoglyco-
sides); The latter two being administered together, because induced a synergistic bactericidal 
effect [32]. 
Moreover, standard protocols for antimicrobial use in cell culture medium are not re-
ported in the literature as well the concentrations that are able to influence cellular responses. 
Therefore, the aim of the present study was evaluate the changes in glutamatergic, oxidative 
and inflammatory parameters related to the use of different classes and concentrations of anti-
microbials in cortical astrocyte cultures. 
2. MATERIAL AND METHODS 
 
Reagents 
Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12) and other materials for cell 
cultures were purchased from Gibco (Carlsbad, CA, USA) ; ELISA for TNF- α and IL-1β were 
purchased from PeproTech (Rocky Hill, NJ, USA); polyclonal anti-GFAP was purchased from 
Dako (Carpinteria, CA, USA); polyclonal anti-GLUT1 from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA); polyclonal anti-GS and anti-GAPDH were from Sigma (St. Louis, MO, USA); 
polyclonal anti-GLAST and anti-GLT1 were from Alpha Diagnostic (San Antonio, TX, USA); 
L-[3H]-glutamate, 2-Deoxy-D-[1,2-3H]glucose ([3H]2DG), nitrocellulose membrane and ECL 
kit were from Amersham (Buckinghamshire, UK). Lastly, both antimicrobials Penicillin/Strep-
tomycin and Gentamicin were purchased from Gibco (Carlsbad, CA, USA). 
 
Animals 
Newborn male Wistar rats were obtained from our breeding colony (Department of Bi-
ochemistry, UFRGS, Brazil) and maintained in a controlled environment (12 hours light/12 
hours dark cycle; 22 ± 1ºC; ad libitum access to food and water). All animal experiments were 
performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and 
were approved by the Federal University of Rio Grande do Sul’s Animal Care and Use Com-
mittee (process number 29180). 
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Primary astrocyte cultures 
The cortices were removed from the animals and dipped in Hank’s Balanced Salt Solu-
tion (HBSS). These structures were undergo enzymatic, mechanical and centrifugal dissocia-
tion steps. The cells were seeded and cultured in DMEM/F12 culture medium containing 10% 
fetal bovine serum (SFB) in a 37 °C incubator in an atmosphere containing 5% CO2 until they 
reach confluence, which occurs around 10 days [25, 33]. The culture environment was con-
tained the different concentrations of the following antibiotics: penicillin [20 U/ml]/streptomy-
cin [0.02 mg/ml], penicillin [100 U/ml]/streptomycin [0.1 mg/ml], penicillin [200 U/ml]/strep-
tomycin [0.2 mg/ml] or gentamicin [0.1 mg/ml, 0.05 mg/ml, 0.025 mg/ml]. Once the cells 
reached confluence, they were used for neurochemical experiments. 
 
Immunocytochemistry 
Immunocytochemistry was performed as described previously by our group [34]. 
Briefly, cell cultures were fixed with 4% paraformaldehyde for 20 minutes and permeabilized 
with 0.1% Triton X-100 in PBS for 5 minutes at room temperature. After blocking overnight 
with 4% albumin, the cells were incubated overnight with anti-GFAP (1:400) at 4°C; this was 
followed by PBS washes and incubation with a specific secondary antibody conjugated with 
Alexa Fluor® 488 (green staining) for 1 hour at room temperature. For all immunostaining-
negative controls, the reactions were performed by omitting the primary antibody. No reactivity 
was observed when the primary antibody was excluded. For actin-labeling analyses, the cells 
werencubated with 10 mg/ml rhodamine-labeled phalloidin in PBS for 45 min and two washes 
with PBS. Cell nuclei were stained with 0.2 μg/ml of 4’,6’-diamidino-2- phenylindole (DAPI). 
The cells were visualized with a Nikon inverted microscope and the images were transferred to 
a computer with a digital camera (Sound Vision Inc.). 
Western Blot Analysis 
Astrocytes were solubilized in lyses solution containing 4 % SDS, 2-mM EDTA and 
50-mM Tris–HCl (pH 6.8). Samples were separated by SDS/PAGE (45 mg protein per sample), 
and transferred to nitrocellulose membranes, which were then incubated overnight (4 °C) with 
one of the following antibodies: anti-GFAP (1:1000), anti-GLT-1 (1:1000), anti-GLAST 
(1:1000), anti-GS (1:10000), anti-GLUT1 (1:1000) or anti-GAPDH (1:1500). GAPDH was 
used as a loading control. Then, the membranes were incubated with a peroxidase-conjugated 
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anti-rabbit immunoglobulin (IgG) or with peroxidase conjugated anti-mouse (IgG) at a dilution 
of 1:20000 for 2 hours. Chemiluminescence signals were detected in an Image Quant LAS4010 
system (GE Healthcare) using an ECL kit [34]. The results are expressed as percentages relative 
to the lowest antimicrobial concentration. 
Glutamate uptake 
After the cells reached confluence, the glutamate uptake was performed as previously 
described [35] with some modifications. Briefly, astrocytes were incubated at 37°C in HBSS 
containing the following components (in mM): 137 NaCl, 5.36 KCl, 1.26 CaCl2, 0.41 MgSO4, 
0.49 MgCl2, 0.63 Na2HPO4, 0.44 KH2PO4, 4.17 NaHCO3 and 5.6 glucose, adjusted to pH 7.4. 
The assay was started by the addition of 0.1 mM L-glutamate and 0.33 µCi/ml L-[2,3-3H] glu-
tamate. The incubation was stopped after 7 minutes by removal of the medium and rinsing the 
cells twice with ice-cold HBSS. The cells were then lysed in a solution containing 0.5 M NaOH. 
Incorporated radioactivity was measured in a scintillation counter. Sodium-independent uptake 
was determined using N-methyl-D-glucamine instead of sodium chloride. Sodium-dependent 
glutamate uptake, considered “specific uptake”, was obtained by subtracting the sodium-inde-
pendent uptake from the total uptake. 
Glutamine synthetase activity 
After the cells reached confluence, the GS (EC 6.3.1.2) activity was performed as pre-
viously described [36]. Briefly, cell homogenate (0.1 ml – about 50 µg) was added to 0.1 ml of 
the reaction mixture containing (in mM): 10 MgCl2, 50 L-glutamate, 100 imidazole-HCl buffer 
(pH 7.4), 10 2-mercaptoethanol, 50 hydroxylamine-HCl and 10 ATP, and incubated for 15 
minutes (37°C). The reaction was stopped by the addition of 0.4 ml of a solution containing (in 
mM): 370 ferric chloride, 670 HCl, and 200 trichloroacetic acid. After centrifugation, the ab-
sorbance of the supernatant was measured at 530 nm and compared to the absorbance generated 
using standard quantities of γ-glutamylhydroxamate treated with a ferric chloride reagent. 
2-Deoxy-D-[1,2-3H]glucose ([3H]2DG) uptake 
After cells reached confluence, basal glucose uptake and glutamate-stimulated glucose 
uptake were assessed as previously described [37]. The cells incubated with DMEM/F12 
1%FBS for 2 hours at 37°C. The medium was then replaced by DMEM/F12 supplemented with 
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1%FBS containing 1 µCi/ml [3H]2DG for 20 minutes at 37°C. After incubations, the cells were 
rinsed with HBSS and lysed overnight with NaOH 0.3 M. Incorporated radioactivity was meas-
ured in a scintillation counter. 
Glutathione content 
After the cells reached confluence, GSH levels were assessed as previously descri-
bed [34]. Astrocyte homogenates (by about 50 µg) were diluted in 100 mM sodium phosphate 
buffer (pH 8.0) containing 5 mM EDTA, and the protein was precipitated with 1.7% meta-
phosphoric acid. The supernatant was assayed with o-phthaldialdehyde (1 mg/ml methanol) at 
room temperature for 15 min. Fluorescence was measured using excitation and emission wave-
lengths of 350 and 420 nm, respectively. A calibration curve was performed with standard GSH 
solutions (0–500 µM). GSH concentrations were calculated as nmol/mg protein. 
Superoxide dismutase (SOD) activity 
SOD (EC 1.15.1.1) activity was determined using the RANSOD kit from Randox (Au-
trim, UK). The SOD activity (based on the degree of the inhibition of formazan dye formation) 
in the lysed cells was spectrophotometrically measured at 505 nm. The inhibition of the pro-
duced chromogen was proportional to the activity of SOD present in the sample. The results 
are expressed as percentages relative to the control conditions. 
Inflammatory Response Measurement 
The TNF-α levels were measured in an extracellular medium using a rat TNF-α ELISA 
kit from Thermo. The levels of interleukins were measured in an extracellular medium using 
ELISA kits for IL-1β, IL-6 and IL-10 from Thermo. The results are expressed in nanogram per 
milliliter. The average minimum sensitivity of the ELISA kit detection is 0.4 ng/ml of cyto-
kines. 
3. RESULTS 
Evaluation of astrocytic cytoskeleton proteins cultivated with different antimicrobial 
The purity of the astrocyte cultures was assessed using cytoskeletal protein GFAP. Im-
munocytochemical analyses showed an intense cytoplasmic immunolabeling for GFAP and 
gentamicin or penicillin/streptomycin did not change the immunolabeling (Fig. 1a; Fig 2a). 
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Using immunoblotting analyses, we observed no significant changes in GFAP expression rela-
tive to the 0.025 mg/ml concentration (adopted as control) in cells cultivated with gentamicin 
(Fig. 1b). In the same way, the astrocytes cultivated with penicillin/streptomycin, did also not 
change GFAP expression relative to the 20 U/ml or 0.02 mg/ml concentration (adopted as con-
trol) (Fig. 2b). 
Typically, cultured rat astrocytes show a polygonal to fusiform and flat morphology, 
and these characteristics were also observed here in cortical astrocytes. Furthermore, actin cy-
toskeleton is the major determinant of the cell morphology, and our astrocyte cultures cultivated 
with gentamicin showed significant staining for actin with parallel arrangement of stress fiber 
(Fig. 1a), whereas those cultivated with penicillin/streptomycin showed changes in parallel ar-
rangement (Fig. 2a). 
Increase in antimicrobial concentrations is accompanied by increase in glutamate uptake 
A significant dose-dependent increase was observed in the glutamate uptake in astro-
cytes cultivated with both gentamicin (from 3.7 to 6.1 nmol/mg protein/min, P = 0.0004, com-
pared to the lower concentration 0.025 mg/ml with 0.1 mg/ml; Fig. 3a) and penicillin/strepto-
mycin (from 3.8 to 8 nmol/mg protein/min, P < 0.001, compared to the lower concentration 20 
U/ml/0.02 mg/ml with 200 U/ml/0.2 mg/ml; Fig. 3d). These cells remove glutamate from the 
extracellular environment through the activity of GLT-1 and GLAST transporters [17]. In this 
sense, we did not observe changes in the expression of GTL-1 and GLAST in cells cultivated 
with both antibiotics (Fig. 3b, c, e, f). 
Once taken up by astrocytes, glutamate is converted into glutamine by GS, which is 
constitutively expressed by astrocytes. The western blotting analyses indicate no alteration in 
the GS expression as well as in the GS activity in the cells cultivated with two antimicrobials 
(Fig. 4a, b, c, d). 
Glucose uptake and GLUT1 transporter expression showed changes in astrocytes culti-
vated with antimicrobials 
Astrocytes are capable of capturing blood glucose, providing energy for maintaining 
neuronal activity. This process is performed by the GLUT1 transporter, which is expressed by 
these cells [22]. Based on that, we observed that glucose uptake was significant reduced (from 
27 to 22 nmol/mg protein/min, P = 0.0447; Fig. 5a) in astrocytes cultivated with 0.1 mg/ml of 
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gentamicin compared to the lowest concentration 0.025 mg/ml. We also observed a significant 
decrease (from 16% to 5%, P = 0,0529; Fig.5b ) in the GLUT1 transporter expression in astro-
cytes cultivated in a medium containing the highest concentration of gentamicin. On the other 
hand, cells cultivated with 200 U/ml/0.2 mg/ml penicillin/streptomycin in the medium pre-
sented an increase in glucose uptake (from 83 to 127 nmol/mg protein/min, P = 0.0076; Fig. 
5c). Penicillin/Streptomycin, in all evaluated concentrations, did not change GLUT1 expression 
levels (Fig 5d). 
Alteration in the system of antioxidant defenses in the astrocytic cells cultivated with gen-
tamicin and penicillin/streptomycin 
We evaluated the levels of GSH - non-enzymatic antioxidant defense - and we observed 
a significant increase in GSH content only in the astrocytes cultivated with 0.1 mg/ml of gen-
tamicin compared to 0.025 mg/ml (from 2,9 to 3,9 nmol/mg protein, P =0.0185; Fig 6a). How-
ever, in cells cultivated with penicillin/streptomycin, GSH levels did not change (Fig. 6c). Con-
cerning to the enzymatic antioxidant defenses we evaluated the SOD activity – capable of dis-
muting the radical superoxide to hydrogen peroxide. Thus, we did not observe significant alter-
ations in SOD activity of astrocytes cultivated with gentamicin nor penicillin/streptomycin (Fig. 
6b, d). 
Changes in the inflammatory response in astrocytes exposed to distinct antimicrobial 
Astrocytes actively participate in the inflammatory response releasing anti- and proin-
flammatory cytokines [38]. As shown in Fig. 7b in cells cultivated with gentamicin increased 
the levels of IL-1β (from 39 to 46 ng/ml, P < 0.0001, compared the concentration 0.025 mg/ml 
and 0.05 mg/ml with 0.1 mg/ml). While the anti-inflammatory IL-10 levels were decreased 
(from 41 to 37 ng/ml, P = 0.0300, compared the concentration 0.025 mg/ml with 0.1 mg/ml; 
Fig. 7d) in the same cultures. However, TNF-α and IL-6 levels showed no significant alterations 
among different concentrations. On the other hand, in cells cultivated with penicillin/strepto-
mycin, we observed an increase in the proinflammatory cytokine IL-6 levels (from 34 to 40 
ng/ml, P = 0.0185 compared the concentration 20 U/ml/0.2 mg/ml with 200 U/ml/0.2 mg/ml; 
Fig. 7g). At the same time, the other pro inflammatory cytokines TNF-α and IL-1β (Fig. 7e, f) 
demonstrated no significant changes as well as we did not observe alterations in the anti-in-
flammatory cytokine IL-10 (Fig. 7h). 
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4. DISCUSSION 
The astrocytes are majority in the CNS and represent approximately half of the cells of 
the human brain [39, 40]. These cells are highly variable in morphology and function, being 
essential in CNS homeostasis [39]. Cell culture is a widely used technique, since it is possible 
to recreate an ideal environment for the cells in vitro, mimicking pathophysiological conditions 
that occur in vivo. This environment consists of nutrients and essential factors for its survival, 
and also needs to be free from microbial contaminations, as the coexistence of cells with mi-
croorganisms might alter specific cellular responses. In this sense, antimicrobials are usually 
added to the cell culture medium in order to make the environment aseptic. Among the most 
used drugs to obtain this asepsis are gentamicin, penicillin and streptomycin; the latter two 
being administered together. 
Gentamicin - produced by an actinomycete, Micromonospora purpurea - is an antimi-
crobial that has a half-life of 2.5 hours. It belongs to the class of aminoglycosides and is used 
against Gram-negative bacteria resistant to other drugs, at the same time that it presents a certain 
degree of toxicity [41]. On the other hand, the Penicillin is part of the beta-lactam group, has a 
half-life of 0.5 to 0.7 hours and is obtained from a fluid culture extract of the fungus Penicillium 
notatum; Being even effective against Gram-positive bacteria and presenting low toxicity [32]. 
Last, the Streptomycin - isolated from a soil microorganism, Streptomyces griseus; its half-life 
is 2 to 3 hours and belongs to the class of aminoglycosides - which is effective against Gram-
negative bacteria and has high toxicity [32]. 
Taking back the context of the astrocytic cultures management and considering the 
above antimicrobials, in this work we evaluate the energetic metabolism of these cells, which 
we focused on the glutamate uptake. This function has great importance for the proper CNS 
functioning. Sodium-dependent astrocytic uptake is the most important for the maintenance of 
physiological extracellular levels of glutamate, avoiding its excitotoxic potential. This process 
is accomplished through the activity of GLT-1 and GLAST transporters [42], which are ex-
pressed by astrocytes. Based on these concepts, we observed a dose-dependent increase in glu-
tamate uptake in cells cultivated with both antimicrobials gentamicin and penicillin/streptomy-
cin, which could indicate some cells responsive profile against these two drugs [43]. Further-
more, we verified the immunocontent of the two astrocytic glutamate transporters and no sig-
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nificant changes were observed in cells cultivated with both antimicrobials. Therefore, the an-
timicrobials were able to increased glutamate uptake, but not have been sufficient to modulate 
the glutamate transporters expression [44].  
After glutamate is taken up by astrocytic transporters, it might be converted to glutamine 
by the enzyme GS - an exclusively astrocytic enzyme in the CNS. This allows these cells an 
important communication route with the neurons through the glutamate-glutamine cycle [45]. 
We evaluated this enzyme - both immunocontent and enzymatic activity - and observed no 
significant changes in the cells cultivated with both antimicrobials. As increased glutamate up-
take did not impact on GS activity, two possible metabolic targets for this neurotransmitter may 
be indicated:  (I) its direct use as  an energy source by conversion to α-ketoglutarate [46]; or 
(II) its use in GSH biosynthesis [47]. 
GSH is a non-enzymatic antioxidant defense that plays its antioxidant effect by reacting 
with reactive oxygen species (ROS), or by being oxidized by the glutathione peroxidase enzyme 
[47, 48]. From these concepts, we evaluated the levels of GSH and no significant changes were 
observed in the cells that had the antimicrobial penicillin/streptomycin added to their culture 
medium [46]. On the other hand, in cells cultivated with gentamicin, there was an increase of 
GSH levels at all concentrations evaluated. In particular, a increase in the highest concentration 
(0.1 mg/ml). This alteration might be justified by the increase in glutamate uptake. As it is used 
in the synthesis of GSH - the enzyme γ-glutamyl-cysteinyl synthetase catalyzes the bind be-
tween glutamate and cysteine to form the γ-glutamyl-cysteinyl dipeptide, which might follow 
the astrocytic GSH pathway or might be exported from astrocytes and be used as a substrate for 
neuronal GSH biosynthesis [47]. With regard to the enzymatic antioxidant defenses we can 
highlight the SOD, which is able to dismutate the superoxide radical to hydrogen peroxide [49]. 
After evaluating the activity of this enzyme, we observed no significant change in the cells 
cultivated with both antimicrobials. This tends to indicate that was not necessary a cellular de-
fense - action of SOD - in response to these antimicrobials; since GSH, being an important 
antioxidant defense, might be reacting and containing any excessive production of ROS [20, 
50]. 
Still on the energetic metabolism of these cells, we evaluated GLUT1 – the main astro-
cytic transporter of glucose - that captures and distributes glucose in the intracellular environ-
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ment, having two important destinations in the astrocytic cells: the glycolytic and the glyco-
genic pathways [22]. When evaluating the immunocontent of this transporter and the glucose 
uptake, in cells cultivated with gentamicin, we identified a significant reduction of both glucose 
uptake and expression.  This occurred only in the medium with the highest antimicrobial con-
centration. In addition, the evaluation of glucose uptake in response to penicillin/streptomycin, 
the highest concentration of antimicrobial was also highlighted, but this time as a significant 
increase. The significant reduction - uptake and immunocontent - in the culture medium con-
taining gentamicin might be explained by the cells needs a stimulus to capture glucose. For this, 
we can suggest as an explanation the increase of glutamate uptake, as it already serves as an 
important energetic source for the cell [51]. Based on that, since the cell apparently does not 
need a high glucose demand, because it has glutamate as energetic source, it is possible that it 
leads to a reduction of GLUT1 expression, which promotes a reduction in glucose uptake. Also, 
in cells cultivated with penicillin/streptomycin, these antimicrobials were able to increase the 
glucose uptake [46], but not sufficient to modulate the GLUT1 expression.  
In addition to the functions already mentioned, these cells can also recognize the early 
inflammatory process events, as well as respond and amplify microglial signaling [3]. These 
cells release a range of anti and proinflammatory cytokines [3, 52]. Therefore, we evaluated the 
levels of these cytokines and observed significant alterations in both culture medium; indicating 
that these drugs are causing an inflammatory process. In addition, changes in the levels of these 
cytokines - pro or anti-inflammatory - may indicate damage to immune homeostasis (IL-10) 
[53, 54] and/or activate the inflammatory process (IL-6 and IL-1β) [55, 56]. 
The cytoskeletal intermediate protein, GFAP - immunocontent and immunocytochem-
istry were analyzed - no significant changes were observed in cells cultivated with gentamicin; 
once the presence of significant changes in protein expression may indicate cell damage [13]. 
This unaltered levels of GFAP may be due to the action of GSH - it refers to the physiological 
state of the cell - containing ROS overproduction [47, 57]. The actin cytoskeleton was also 
analyzed, which is a highly dynamic structure that is continuously reorganized whenever the 
cell responds to the environment, either by altering its shape or by suffering division [58]. In 
cells cultured with gentamicin, no changes were observed in actin structure. In cells cultivated 
with penicillin/streptomycin, we also observed no significant changes in both GFAP immuno-
content and immunocytochemistry. In the actin cytoskeleton, we observed modifications in the 
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classical arrangement. The presence of modifications may indicate signal transmission, which 
leads to an adequate cellular response [58]. Thus, concomitant with the increase observed in 
proinflammatory cytokines might lead the actin cytoskeleton reorganization [59].  
Finally, the findings here described suggest that antimicrobials used in culture medium 
to prevent contamination may alter astrocytic functionality. Thus, the non-standard use of such 
drugs in cell cultures may explain possible contrasts between experiments performed by differ-
ent research groups. Thus, it is important to formulate standardized protocols on the addition of 
these antimicrobials to the culture medium. 
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Fig 1. Evaluation of astrocytic cytoskeleton proteins cultivated with gentamicin. (A) Immunostaining for GFAP 
and staining for actin in different concentrations of gentamicin (B) Representative immunoblot of GFAP (n=6). 
The bar graph corresponds to the mean ± S.E.M. and represents the percentages relative to the 0.025 mg/ml con-
centration (adopted as control). The data were generated in two independent experiments and analyzed statistically 
using one-way ANOVA followed by Tukey’s test. 
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Fig 2. Evaluation of astrocytic cytoskeleton proteins cultivated with penicillin/streptomycin. (A) Immunostaining 
for GFAP and staining for actin in different concentrations of penicillin/streptomycin. (B) Representative im-
munoblot of GFAP (n=6). The bar graph corresponds to the mean ± S.E.M. and represents the percentages relative 
to the 20 U/ml/0.02 mg/ml concentration (adopted as control). The data were generated in two independent exper-
iments and analyzed statistically using one-way ANOVA followed by Tukey’s test. 
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Fig 3. Increase in antimicrobial concentration induced by increase in glutamate uptake. (A) Glutamate uptake. 
Quantification of (B) GLT-1 and (C) GLAST in astrocytes cultivated with gentamicin. (D) Glutamate uptake, (F) 
Quantification of GLT-1 and (G) GLAST in astrocytes cultivated with penicillin/streptomycin. Data are expressed 
as the mean ± S.E.M. and represents the percentages relative to the lowest antimicrobial concentration (adopted as 
control). The data were generated in four independent experiments with n=6 and analyzed statistically using one-
way ANOVA followed by Tukey’s test. Values of p < 0.05 were consider significant. a Indicates differences from 
lowest antimicrobial concentration; b Indicates differences from intermediate antimicrobial concentration. 
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Fig 4. Effects of antimicrobials on GS activity and expression in astrocyte primary cultures. (A) GS activity and 
(B) GS immunocontent in astrocytes cultivated with gentamicin. (C) GS activity and (B) GS immunocontent in 
astrocytes cultivated with penicillin/streptomycin. Data are expressed as the mean ± S.E.M. and represents the 
percentages relative to the lowest antimicrobial concentration (adopted as control). The data were generated in 
four independent experiments with n=6 and analyzed statistically using one-way ANOVA followed by Tukey’s 
test. 
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Fig 5. Glucose uptake and GLUT1 transporter expression showed changes in astrocytes cultivated with antimicro-
bials. (A) Glucose uptake and (B) GLUT1 expression in astrocyte cultivated with gentamicin (C) Glucose uptake 
and (D) GLUT1 expression in astrocytes cultivated with penicillin/streptomycin. Immunoblots (n=6) data are ex-
pressed as the mean ± S.E.M. and represents the percentages relative to the lowest antimicrobial concentration 
(adopted as control). Analyzed statistically using one-way ANOVA followed by Tukey’s test.  Values of p < 0.05 
were consider significant. a Indicates differences from lowest antimicrobial concentration; b Indicates differences 
from intermediate antimicrobial concentration. 
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Fig 6. Alteration in the system of antioxidant defenses in the astrocytic cells cultivated with gentamicin and peni-
cillin/streptomycin. (A) GSH levels and (B) SOD activity in astrocytes cultivated with gentamicin. (C) GSH levels 
and (D) SOD activity in astrocytes cultivated with penicillin/streptomycin. Analyzed statistically using one-way 
ANOVA followed by Tukey’s test. Values of p < 0.05 were consider significant. a Indicates differences from 
lowest antimicrobial concentration; b Indicates differences from intermediate antimicrobial concentration. 
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Fig 7. Changes in the inflammatory response of astrocytes exposed to distinct antimicrobial.  (A) TNF-α, (B) IL-
1β, (C) IL-6 and (D) IL-10 levels in astrocytes cultivated with gentamicin. (E) TNF-α, (F) IL-1β, (G) IL-6 and (H) 
IL-10 levels in astrocytes cultivated with penicillin/streptomycin. Analyzed statistically using one-way ANOVA 
followed by Tukey’s test. Values of p < 0.05 were consider significant. a Indicates differences from lowest anti-
microbial concentration; b Indicates differences from intermediate antimicrobial concentration. 
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5. CONCLUSÕES E PERSPECTIVAS  
 Os resultados obtidos neste trabalho sugerem que os antimicrobianos adicionados aos 
meios de cultivos interferem no metabolismo celular. Pois, observamos algumas alterações no 
metabolismo energético, nas defesas antioxidantes, no citoesqueleto de actina e, ainda, na res-
postas inflamatória. Sendo assim, o uso não padronizado desses antimicrobianos pode explicar 
as discrepâncias entre experimentos realizados por diferentes grupos de pesquisas. A partir 
disso, percebemos que existe uma necessidade de formular protocolos acerca dos tipos de fár-
macos e de suas concentrações que serão adicionadas aos meios.  
 Como perspectivas pretendemos avaliar a ceftriaxona, esse antimicrobiano também 
pode ser adicionado aos meios de cultivo como uma técnica de assepsia. Esse fármaco demons-
trou ser capaz de atuar diretamente na modulação do sistema glutamatérgico, aumentando a 
captação de glutamato e a expressão de GLT-1 (Rothstein et al., 2005). Além disso, pretende-
mos realizar mais experimentos neuroquímicos como: avaliação do imunoconteúdo e secreção 
dos fatores tróficos o fator neurotrófico derivado da glia (GDNF) e o fator neurotrófico derivado 
do encéfalo (BDNF), atividade das enzimas CAT e GPx e avaliar produção das espécies reativas 
de oxigênio (DCFH).  
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Book 
South J, Blass B (2001) The future of modern genomics. Blackwell, London 
Book chapter 
Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern 
genomics, 3rd edn. Wiley, New York, pp 230-257 
Online document 
Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. 
http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007 
Dissertation 
Trent JW (1975) Experimental acute renal failure. Dissertation, University of 
California 
Always use the standard abbreviation of a journal’s name according to the ISSN List 
of Title Word Abbreviations, see 
ISSN.org LTWA 
If you are unsure, please use the full journal title. 
For authors using EndNote, Springer provides an output style that supports the formatting of 
intext citations and referenc list. EndNote style (zip, 2 kB). Authors preparing their manuscript 
in LaTeX can use the bibtex file spbasic.bst which is included in Springer’s LaTeX macro pack-
age. 
TABLES 
All tables are to be numbered using Arabic numerals; Tables should always be cited in text in 
consecutive numerical order; For each table, please supply a table caption (title) explaining the 
components of the table; Identify any previously published material by giving the original 
source in the form of a reference at the end of the table caption; Footnotes to tables should be 
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indicated by superscript lower-case letters (or asterisks for significance values and other statis-
tical data) and included beneath the table body. 
ARTWORK AND ILLUSTRATIONS GUIDELINES 
Electronic Figure Submission 
Scanned line drawings and line drawings in bitmap format should have a minimum resolution 
of 1200 dpi. 
Vector graphics containing fonts must have the fonts embedded in the files. 
Halftone Art 
Definition: Photographs, drawings, or paintings with fine shading, etc. 
If any magnification is used in the photographs, indicate this by using scale bars within the 
figures themselves. 
Halftones should have a minimum resolution of 300 dpi.  
Combination Art 
Definition: a combination of halftone and line art, e.g., halftones containing line  drawing, ex-
tensive lettering, color diagrams, etc. 
Combination artwork should have a minimum resolution of 600 dpi. 
Color Art 
Color art is free of charge for online publication.  
If black and white will be shown in the print version, make sure that the main information will 
still be visible.  
Many colors are not distinguishable from one another when converted to black and white.  
A simple way to check this is to make a xerographic copy to see if the necessary distinctions 
between the different colors are still apparent. 
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If the figures will be printed in black and white, do not refer to color in the captions.  
Color illustrations should be submitted as RGB (8 bits per channel). 
Figure Lettering 
To add lettering, it is best to use Helvetica or Arial (sans serif fonts). 
Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 
mm (8–12 pt). 
Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type 
on an axis and 20-pt type for the axis label. 
Avoid effects such as shading, outline letters, etc. 
Do not include titles or captions within your illustrations. 
Figure Numbering 
All figures are to be numbered using Arabic numerals; Figures should always be cited in text 
in consecutive numerical order; Figure parts should be denoted by lowercase letters (a, b, c, 
etc.); If an appendix appears in your article and it contains one or more figures, continue the 
consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, 
etc." Figures in online appendices (Electronic Supplementary Material) should, however, be 
numbered separately. 
Figure Captions 
Each figure should have a concise caption describing accurately what the figure depicts. 
Include the captions in the text file of the manuscript, not in the figure file. 
Figure captions begin with the term Fig. in bold type, followed by the figure number, also 
in bold type. 
No punctuation is to be included after the number, nor is any punctuation to be placed at 
the end of the caption. 
Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., 
as coordinate points in graphs. 
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Identify previously published material by giving the original source in the form of a reference 
citation at the end of the figure caption. 
Figure Placement and Size 
Figures should be submitted separately from the text, if possible. 
When preparing your figures, size figures to fit in the column width. 
For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not 
higher than 234 mm. 
For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not 
higher than 198 mm. 
Permissions 
If you include figures that have already been published elsewhere, you must obtain permission 
from the copyright owner(s) for both the print and online format. Please be aware that some 
publishers do not grant electronic rights for free and that Springer will not be able to refund 
any costs that may have occurred to receive these permissions. In such cases, material from 
other sources should be used. 
Accessibility 
In order to give people of all abilities and disabilities access to the content of your figures, 
please make sure that 
All figures have descriptive captions (blind users could then use a text-to-speech software or 
a text-to-Braille hardware) 
Patterns are used instead of or in addition to colors for conveying information (colorblind users 
would then be able to distinguish the visual elements) Any figure lettering has a contrast ratio 
of at least 4.5:1 
ELECTRONIC SUPPLEMENTARY MATERIAL 
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supple-
mentary files to be published online along with an article or a book chapter. This feature can 
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add dimension to the author's article, as certain information cannot be printed or is more con-
venient in electronic form. 
Before submitting research datasets as electronic supplementary material, authors should 
read the journal’s Research data policy. We encourage research data to be archived in data 
repositories wherever possible. 
Submission 
Supply all supplementary material in standard file formats.Please include in each file the fol-
lowing information: article title, journal name, author names; affiliation and e-mail address of 
the corresponding author. To accommodate user downloads, please keep in mind that 
larger-sized files may require very long download times and that some users may experience 
other problems during downloading. 
Audio, Video, and Animations 
Aspect ratio: 16:9 or 4:3 / Maximum file size: 25 GB / Minimum video duration: 1 sec 
Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp 
Text and Presentations 
Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability. 
A collection of figures may also be combined in a PDF file. 
Spreadsheets 
Spreadsheets should be submitted as .csv or .xlsx files (MS Excel). 
Specialized Formats 
Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), 
and .tex can also be supplied. 
Collecting Multiple Files 
55 
 
  
 
It is possible to collect multiple files in a .zip or .gz file. 
Numbering 
If supplying any supplementary material, the text must make specific mention of the material 
as a citation, similar to that of figures and tables. 
Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the ani-
mation (Online Resource 3)", “... additional data are given in Online Resource 4”. 
Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”. 
Captions 
For each supplementary material, please supply a concise caption describing the content of 
the file. 
Processing of supplementary files 
Electronic supplementary material will be published as received from the author without 
any conversion, editing, or reformatting. 
Accessibility 
In order to give people of all abilities and disabilities access to the content of your supplemen-
tary files, please make sure that 
The manuscript contains a descriptive caption for each supplementary material 
Video files do not contain anything that flashes more than three times per second (so that users 
prone to seizures caused by such effects are not put at risk) 
ENGLISH LANGUAGE EDITING 
For editors and reviewers to accurately assess the work presented in your manuscript you need 
to ensure the English language is of sufficient quality to be understood. If you need help with 
writing in English you should consider: 
Asking a colleague who is a native English speaker to review your manuscript for clarity. 
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Visiting the English language tutorial which covers the common mistakes when writing 
in English. 
Using a professional language editing service where editors will improve the English to 
ensure that your meaning is clear and identify problems that require your review. Two 
such services are provided by our affiliates Nature Research Editing Service and Amer-
ican Journal Experts. 
English language tutorial 
Nature Research Editing Service 
American Journal Experts 
Please note that the use of a language editing service is not a requirement for publication in this 
journal and does not imply or guarantee that the article will be selected for peer review or ac-
cepted. 
If your manuscript is accepted it will be checked by our copyeditors for spelling and formal 
style before publication. 
ETHICAL RESPONSIBILITIES OF AUTHORS 
This journal is committed to upholding the integrity of the scientific record. As a member of 
the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on 
how to deal with potential acts of misconduct. 
Authors should refrain from misrepresenting research results which could damage the trust in 
the journal, the professionalism of scientific authorship, and ultimately the entire scientific 
endeavour. Maintaining integrity of the research and its presentation can be achieved by fol-
lowing the rules of good scientific practice, which include: 
The manuscript has not been submitted to more than one journal for simultaneous considera-
tion. 
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The manuscript has not been published previously (partly or in full), unless the new 
work concerns an expansion of previous work (please provide transparency on the 
re-use of material to avoid the hint of text-recycling (“self-plagiarism”)). 
A single study is not split up into several parts to increase the quantity of submissions 
and submitted to various journals or to one journal over time (e.g. “salami-publishing”). 
No data have been fabricated or manipulated (including images) to support your conclusions 
No data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). 
Proper acknowledgements to other works must be given (this includes material that is closely 
copied (near verbatim), summarized and/or paraphrased), quotation marks are used for verbatim 
copying of material, and permissions are secured for material that is copyrighted. 
Important note: the journal may use software to screen for plagiarism. 
Consent to submit has been received explicitly from all co-authors, as well as from the 
responsible authorities - tacitly or explicitly - at the institute/organization where the 
work has been carried out, before the work is submitted. 
Authors whose names appear on the submission have contributed sufficiently to the 
scientific work and therefore share collective responsibility and accountability for the 
results. 
Authors are strongly advised to ensure the correct author group, corresponding author, 
and order of authors at submission. Changes of authorship or in the order of authors are 
not accepted after acceptance of a manuscript. 
Adding and/or deleting authors at revision stage may be justifiably warranted. A letter 
must accompany the revised manuscript to explain the role of the added and/or deleted 
author(s). Further documentation may be required to support your request. 
Requests for addition or removal of authors as a result of authorship disputes after ac-
ceptance are honored after formal notification by the institute or independent body 
and/or when there is agreement between all authors. 
Upon request authors should be prepared to send relevant documentation or data in order 
to verify the validity of the results. This could be in the form of raw data, samples, rec-
ords, etc. Sensitive information in the form of confidential proprietary data is excluded. 
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If there is a suspicion of misconduct, the journal will carry out an investigation following the 
COPE guidelines. If, after investigation, the allegation seems to raise valid concerns, the ac-
cused author will be contacted and given an opportunity to address the issue. If misconduct 
has been established beyond reasonable doubt, this may result in the Editor-in-Chief’s imple-
mentation of the following measures, including, but not limited to: 
If the article is still under consideration, it may be rejected and returned to the author. 
If the article has already been published online, depending on the nature and severity of 
the infraction, either an erratum will be placed with the article or in severe cases com-
plete retraction of the article will occur. The reason must be given in the published er-
ratum or retraction note. Please note that retraction means that the paper is maintained 
on the platform, watermarked "retracted" and explanation for the retraction is provided 
in a note linked to the watermarked article. The author’s institution may be informed. 
COMPLIANCE WITH ETHICAL STANDARDS 
To ensure objectivity and transparency in research and to ensure that accepted principles of 
ethical and professional conduct have been followed, authors should include information re-
garding sources of funding, potential conflicts of interest (financial or non-financial), informed 
consent if the research involved human participants, and a statement on welfare of animals if 
the research involved animals. 
Authors should include the following statements (if applicable) in a separate section entitled 
“Compliance with Ethical Standards” when submitting a paper: 
Disclosure of potential conflicts of interest 
Research involving Human Participants and/or Animals Informed con-
sent 
Please note that standards could vary slightly per journal dependent on their peer review 
policies (i.e. single or double blind peer review) as well as per journal subject discipline. 
Before submitting your article check the instructions following this section carefully. 
The corresponding author should be prepared to collect documentation of compliance with eth-
ical standards and send if requested during peer review or after publication. 
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The Editors reserve the right to reject manuscripts that do not comply with the abovementioned 
guidelines. The author will be held responsible for false statements or failure to fulfill the 
above-mentioned guidelines. 
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST 
Authors must disclose all relationships or interests that could have direct or potential influence 
or impart bias on the work. Although an author may not feel there is any conflict, disclosure of 
relationships and interests provides a more complete and transparent process, leading to an 
accurate and objective assessment of the work. Awareness of a real or perceived conflicts of 
interest is a perspective to which the readers are entitled. This is not meant to imply that a 
financial relationship with an organization that sponsored the research or compensation re-
ceived for consultancy work is inappropriate. Examples of potential conflicts of interests that 
are directly or indirectly related to the research may include but are not limited to the following: 
Research grants from funding agencies (please give the research funder and the grant num-
ber) 
Honoraria for speaking at symposia 
Financial support for attending symposia 
Financial support for educational programs 
Employment or consultation 
Support from a project sponsor 
Position on advisory board or board of directors or other type of management relationships 
Multiple affiliations 
Financial relationships, for example equity ownership or investment interest 
Intellectual property rights (e.g. patents, copyrights and royalties from such rights) Holdings 
of spouse and/or children that may have financial interest in the work 
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In addition, interests that go beyond financial interests and compensation (non-financial inter-
ests) that may be important to readers should be disclosed. These may include but are not lim-
ited to personal relationships or competing interests directly or indirectly tied to this research, 
or professional interests or personal beliefs that may influence your research. 
The corresponding author collects the conflict of interest disclosure forms from all authors. In 
author collaborations where formal agreements for representation allow it, it is sufficient for 
the corresponding author to sign the disclosure form on behalf of all authors. Examples of forms 
can be found here: 
The corresponding author will include a summary statement in the text of the manuscript in a 
separate section before the reference list, that reflects what is recorded in the potential conflict 
of interest disclosure form(s). 
See below examples of disclosures: 
Funding: This study was funded by X (grant number X). 
Conflict of Interest: Author A has received research grants from Company A. Author B has 
received a speaker honorarium from Company X and owns stock in Company Y. Author C is 
a member of committee Z. 
If no conflict exists, the authors should state: 
Conflict of Interest: The authors declare that they have no conflict of interest. 
RESEARCH INVOLVING HUMAN PARTICIPANTS AND/OR ANIMALS 
1) Statement of human rights 
When reporting studies that involve human participants, authors should include a statement that 
the studies have been approved by the appropriate institutional and/or national research ethics 
committee and have been performed in accordance with the ethical standards as laid down in 
the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. 
If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Dec-
laration or comparable standards, the authors must explain the reasons for their approach, and 
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demonstrate that the independent ethics committee or institutional review board explicitly ap-
proved the doubtful aspects of the study. 
The following statements should be included in the text before the References section: 
Ethical approval: “All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and/or national research committee 
and with the 1964 Helsinki declaration and its later amendments or comparable ethical stand-
ards.” 
For retrospective studies, please add the following sentence: 
“For this type of study formal consent is not required.” 
2) Statement on the welfare of animals 
The welfare of animals used for research must be respected. When reporting experiments on 
animals, authors should indicate whether the international, national, and/or institutional guide-
lines for the care and use of animals have been followed, and that the studies have been ap-
proved by a research ethics committee at the institution or practice at which the studies were 
conducted (where such a committee exists). 
For studies with animals, the following statement should be included in the text before the Ref-
erences section: 
Ethical approval: “All applicable international, national, and/or institutional guidelines for the 
care and use of animals were followed.” 
If applicable (where such a committee exists): “All procedures performed in studies involving 
animals were in accordance with the ethical standards of the institution or practice at which the 
studies were conducted.” 
If articles do not contain studies with human participants or animals by any of the authors, 
please select one of the following statements: 
“This article does not contain any studies with human participants performed by any of the 
authors.” 
“This article does not contain any studies with animals performed by any of the authors.” 
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“This article does not contain any studies with human participants or animals performed by any 
of the authors.” 
INFORMED CONSENT 
All individuals have individual rights that are not to be infringed. Individual participants in 
studies have, for example, the right to decide what happens to the (identifiable) personal data 
gathered, to what they have said during a study or an interview, as well as to any photograph 
that was taken. Hence it is important that all participants gave their informed consent in writing 
prior to inclusion in the study. Identifying details (names, dates of birth, identity numbers and 
other information) of the participants that were studied should not be published in written de-
scriptions, photographs, and genetic profiles unless the information is essential for scientific 
purposes and the participant (or parent or guardian if the participant is incapable) gave written 
informed consent for publication. Complete anonymity is difficult to achieve in some cases, 
and informed consent should be obtained if there is any doubt. For example, masking the eye 
region in photographs of participants is inadequate protection of anonymity. If identifying char-
acteristics are altered to protect anonymity, such as in genetic profiles, authors should provide 
assurance that alterations do not distort scientific meaning. 
The following statement should be included: 
Informed consent: “Informed consent was obtained from all individual participants included in 
the study.” 
If identifying information about participants is available in the article, the following statement 
should be included: 
“Additional informed consent was obtained from all individual participants for whom identify-
ing information is included in this article.” 
AFTER ACCEPTANCE 
Upon acceptance of your article you will receive a link to the special Author Query Application 
at Springer’s web page where you can sign the Copyright Transfer Statement online and indi-
cate whether you wish to order OpenChoice, offprints, or printing of figures in color. 
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Once the Author Query Application has been completed, your article will be processed and you 
will receive the proofs. 
Copyright transfer 
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher 
exclusive publication and dissemination rights). This will ensure the widest possible protection 
and dissemination of information under copyright laws. 
Creative Commons Attribution-NonCommercial 4.0 International License 
Offprints 
Offprints can be ordered by the corresponding author. 
Color illustrations 
Online publication of color illustrations is free of charge. For color in the print version, authors 
will be expected to make a contribution towards the extra costs. 
Proof reading 
The purpose of the proof is to check for typesetting or conversion errors and the completeness 
and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, 
corrected values, title and authorship, are not allowed without the approval of the Editor. 
After online publication, further changes can only be made in the form of an Erratum, which 
will be hyperlinked to the article. 
Online First 
The article will be published online after receipt of the corrected proofs. This is the official first 
publication citable with the DOI. After release of the printed version, the paper can also be cited 
by issue and page numbers. 
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OPEN CHOICE 
In addition to the normal publication process (whereby an article is submitted to the journal and 
access to that article is granted to customers who have purchased a subscription), Springer pro-
vides an alternative publishing option: Springer Open Choice. A Springer Open Choice article 
receives all the benefits of a regular subscription-based article, but in addition is made available 
publicly through Springer’s online platform SpringerLink. 
Open Choice 
Copyright and license term – CC BY 
Open Choice articles do not require transfer of copyright as the copyright remains with the 
author. In opting for open access, the author(s) agree to publish the article under the Creative 
Commons Attribution License. 
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